4.5 Article

'Obesity paradox' misunderstands the biology of optimal weight throughout the life cycle

Journal

INTERNATIONAL JOURNAL OF OBESITY
Volume 39, Issue 1, Pages 82-84

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ijo.2014.59

Keywords

healthy aging; reverse causation; obesity epidemic; survival advantage; body mass index

Funding

  1. Allergan Inc
  2. Metagenics
  3. iNova Pharmaceuticals
  4. Medtronic
  5. Servier Australia
  6. Abbott
  7. Allergan Inc.
  8. Pfizer
  9. Wyeth Pharmaceuticals
  10. Servier

Ask authors/readers for more resources

The 'obesity paradox' refers to observations that run counter to the thesis that normal weight (BMI 18.5-24.9 kg/m(2)) provides the lowest mortality and higher weight is associated with greater mortality. We argue that the weight of lowest mortality is influenced by aging and chronic disease, with mortality advantage extending into the overweight and even class I obese ranges under some circumstances. A focus on quality nutrition, physical activity, fitness, and maintaining function in these weight ranges may be preferable to a focus on intentional weight loss, which has uncertain effects. The 'obesity paradox' is no 'paradox' if one defines and interprets 'ideal' weight appropriately.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available